US EPA and NanoLogix to Extend Agreement to 2015

NanoLogix Provides Operations Update

HUBBARD, Ohio--()--NanoLogix Inc. (NNLX), an innovator in the accelerated detection, identification and antibiotic sensitivity determination of live bacteria, announces that the US Environmental Protection Agency and NanoLogix have agreed to extend their existing Cooperative Research and Development Agreement (CRADA) for two years, with the new expiration being mid-2015. The CRADA is focused on using NanoLogix-based technologies for development of a comprehensive water quality test kit for testing drinking and source waters in all ten EPA regions.

NanoLogix continues to develop new products and new markets. The company has advanced in a number of areas, including development of new technologies, increasing sales and customer bases, and gaining substantial recognition in published research on NanoLogix products and techniques.

The technology developments at NanoLogix are revolutionary. Improving on existing bacterial diagnostic products and protocols, the Company is achieving success in the market for its Extended-Life Petri dishes and BNP diagnostic kits, both vacuum-packed in gas-charged FlatPacks. The FlatPack technology – exclusively licensed to NanoLogix – represents a major breakthrough in supply-chain management for these products. Customers using FlatPacked Petri dishes achieve significant cost savings and supply chain efficiencies over traditional Petri dishes available from other suppliers. Our products have virtually no breakage in shipment and storage, and have a shelf life far beyond that of traditional filled Petri dishes. Tests of our select nutrient agars demonstrate a usable shelf life, stored at room temperature, of at least one year. This is four times longer than the competition's filled Petri plates that require cold storage. Not requiring refrigeration of select media in filled Petri plates is one of the most important developments in bacterial culture and Petri in decades and provides the potential for use of our products throughout the world, with cold storage, expiration, and fragility no longer the concerns they have been for many decades. Shelf life tests of our filled Petri plates that are kept in cold storage, to date, have shown a usable shelf life of at least two years. All shelf life tests have been conducted by a major independent third-party research laboratory and are continuing.

Customers to date include the US EPA, independent research and hospital laboratories, and defense contractors. NanoLogix products are at present being used on at least six classified Federal government projects, with expanded use expected this year. Those projects are funded by the US Departments of Defense, Homeland Security, and the US Environmental Protection Agency. In the past month, NanoLogix has hired four new production employees to cope with added demand.

NanoLogix has recently signed agreements with companies and distributors in Europe and Asia governing expansion of our business beyond US borders. The Company is currently in talks with other US and foreign-based corporations on use of BNP, BNF and Petri products. In April the Company received a granted patent in Japan for its BNP diagnostic technology. Since that event interests in Japan have approached NanoLogix regarding purchase of BNP for use in TB research.

In the past year we and our collaborators in research at University of Texas Health Science Center at Houston have made significant refinements to our existing technologies and have also developed one additional rapid test. The new test has been named the N-Assay. The N-Assay is a unique ELISA multi-well machine-readable assay that provides results for bacteria identification and antibiotic sensitivity in less than one hour with high sensitivity and specificity. Indications are that the N-Assay will provide rapid results for any bacteria for which an antibody exists. We at NanoLogix and the researchers using the N-Assay are very excited at this new development. The N-Assay is projected to provide a premier platform for Point-of–Care rapid diagnostics. N-Assay patent filings were made in 2013. It is projected that the N-Assay will be more suitable for use in some developed areas than our BNF identification technology, with the BNF useful in areas or regions that are less developed.

The Company exhibited at three professional conferences this year --- The American Society for Microbiology (ASM) BioDefense and Emerging Diseases Research meeting in Washington, DC in February, the Food Safety Summit in Baltimore, and the ASM Annual Meeting in Denver, both in May. At all of these meetings there was strong interest in our products, with sales and promise of sales as a result. At the Denver ASM meeting, the general and specific interest was far beyond any the Company has experienced at any of the consecutive ASM meetings attended since 2008.

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity

For more information visit www.nanologix.com.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contacts

NanoLogix, Inc.
Investors:
Carol Surrena, 330-534-0800
carol@nanologix.com

Release Summary

US EPA and NanoLogix expand and extend CRADA for clean water testing development. NanoLogix announces breakthroughs in culture and Petri shelf life and diagnostic developments.

Contacts

NanoLogix, Inc.
Investors:
Carol Surrena, 330-534-0800
carol@nanologix.com